Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

NCT03133546

PHASE2INTERVENTIONAL

ETOP IBCSG Partners Foundation

155 participants

Started 2017-05-31 · Completed 2024-02-29

Status: Completed (as of 12-23-2025)

Conditions

Non Small Cell Lung Cancer Metastatic

Interventions

DRUG: Osimertinib DRUG: Bevacizumab

Linked Papers (from SciSciNet-V2)

Total Papers6

Background

2

Result

0

Derived

0

Unknown

4

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small cell lung carcinoma (NSCLC) harbouring activating EGFR (exon 19 deletion or L858R) and T790M resistance mutation.

Sort by:

Background Papers4

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers4

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5,195 citations

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Implications of key trials in advanced nonsmall cell lung cancer